<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00608634</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000582634</org_study_id>
    <secondary_id>P01CA027502</secondary_id>
    <secondary_id>P30CA023074</secondary_id>
    <secondary_id>UARIZ-HSC-04-27</secondary_id>
    <secondary_id>UARIZ-POH-002</secondary_id>
    <nct_id>NCT00608634</nct_id>
  </id_info>
  <brief_title>Topical Perillyl Alcohol in Treating Patients With Sun Damaged Skin and Actinic Keratoses</brief_title>
  <official_title>Phase 2a Randomized, Placebo-Controlled, Double-Blind Trial of Topical Perillyl Alcohol in Sun Damaged Skin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arizona Disease Control Research Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as perillyl alcohol, work in different ways to
      stop the growth of abnormal cells, either by killing the cells or by stopping them from
      dividing. It is not yet known which dose of topical perillyl alcohol is more effective in
      stopping the development of cancer in sun damaged skin.

      PURPOSE: This randomized phase II trial is studying high-dose topical perillyl alcohol to see
      how well it works compared with low-dose topical perillyl alcohol in treating patients with
      sun damaged skin and actinic keratoses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine if topical administration of perillyl alcohol (POH) cream can reverse
           actinic damage as evidenced by normalization of quantitative skin histopathology scores
           in skin tissue biopsy samples from patients with moderate to severe sun damage.

      Secondary

        -  To determine if topical POH can be administered safely to the forearms of these
           patients.

      OUTLINE: Patients are randomized to 1 of 3 arms.

        -  Placebo: Patients apply a placebo cream topically to each dorsal forearm twice daily for
           3 months in the absence of unacceptable toxicity.

        -  Low Dose: Patients apply perillyl alcohol (POH) cream (0.3%) topically to each dorsal
           forearm twice daily for 3 months in the absence of unacceptable toxicity.

        -  High Dose: Patients apply POH cream (0.76%) as in arm II. Patients undergo tissue
           sampling of the right or left dorsal forearm and of physician-selected representative
           actinic keratoses (AK) at baseline and after completion of study therapy. Tissue samples
           are assessed for changes in patterns of biomarker expression (i.e., p53, apoptosis,
           c-Fos histopathology) and karyometry. After completion of study therapy, patients
           undergo tissue sampling of the opposite forearm as well as blood sample collection to
           determine perillyl alcohol (POH) levels in blood and biopsy samples. Urine is also
           collected and analyzed for safety at the end of treatment. Digital photographs of the
           forearms and hands are obtained at baseline and after 3 months of study treatment.
           Optical coherence tomography imaging is also performed on pre- and post-biopsy sites to
           quantify the effect of POH on sun damage and AK in skin.

      After completion of study treatment, patients are followed monthly.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Histopathology Score of Sun Damaged Skin by Treatment Group</measure>
    <time_frame>Baseline to 3 months</time_frame>
    <description>The histopathologic scoring for skin biopsies from sun-damaged skin to assess the following seven characteristics: 1- atypia (levels 0, 1 &amp; 2), 2- inflammation (grades 0, 1 &amp; 2), 3- hyperkeratosis (loss of basket weave pattern of stratum corneum), 4- parakeratosis (present when there were &gt;3 characteristic nuclei per 40:1 field in stratum corneum), 5- dyskeratosis (focal presence of cells with homogenous, pink cytoplasm n pyknotic nuclei), 6- epidermotropism (lymphocytes migration of &gt;3 cells into epidermis, 7- loss of granular layer. All assessments were done using a 40:1 objective.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skin Related Events From Perillyl Alcohol at Administered Doses by Participants</measure>
    <time_frame>3 months</time_frame>
    <description>The events do not have to be caused by the drug or therapy, and they may be mild, moderate, or severe. (NCI)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Precancerous Condition</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients apply a placebo cream topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose POH 0.30%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients apply perillyl alcohol (POH) cream (0.3%) topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose POH 0.76%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients apply perillyl alcohol (POH) cream (0.76%) topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>perillyl alcohol</intervention_name>
    <description>Applied as topical cream</description>
    <arm_group_label>Low Dose POH 0.30%</arm_group_label>
    <arm_group_label>High Dose POH 0.76%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Applied as topical cream</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Resident of Pima or adjoining Southern Arizona county

               -  Patients outside of Pima County are also eligible

          -  Sun damaged skin as judged by the study physician and quantifiable, clinically
             diagnosed, and visible actinic keratoses (AK) on both dorsal forearms, with at least
             two AK on each arm

               -  AK lesions must not be clustered, confluent, or too numerous to count accurately

               -  Presence of AK on sites other than the test area allowed

          -  No significant inflammation or irritation of the skin of the upper extremities that is
             not clinically diagnosed as sun damage or AK

          -  Patients must agree to limit sun exposure as much as possible and may continue their
             normal pattern of sunscreen use

        PATIENT CHARACTERISTICS:

        Inclusion criteria:

          -  Females must not be of childbearing potential, and therefore must be post-menopausal
             or surgically sterile by hysterectomy

          -  Not pregnant or nursing

        Exclusion criteria:

          -  Concurrent skin malignancy or disorder of the upper extremities

               -  Patients with Squamous cell carcinoma or basal cell carcinoma in an area other
                  than the test area are eligible upon excision of the Squamous cell carcinoma or
                  basal cell carcinoma

          -  Patients who are immunosuppressed by virtue of medication or disease

          -  Serious concurrent illness that could interfere with study regimen

          -  Invasive cancer within the past 5 years

        PRIOR CONCURRENT THERAPY:

          -  At least 30 days since prior topical medications to the skin of the upper extremities
             except for emollients or sunscreens

          -  At least 30 days since prior and no concurrent mega-doses of vitamins, defined as any
             of the following:

               -  More than 5 times the recommended daily allowance

               -  More than 5 capsules of multivitamins

               -  400 IU of vitamin E

               -  200 Î¼g of selenium

               -  1 gm of vitamin C

          -  At least 6 months since prior and no concurrent therapy for squamous cell carcinoma
             (SCC) or basal cell carcinoma (BCC) anywhere in the test area (i.e., the forearms or
             hands)

               -  Treatment for Squamous cell carcinoma or basal cell carcinoma on sites other than
                  the test area is allowed

          -  At least 4 weeks since prior surgical biopsy, surgical excision, or cryotherapy for AK
             in the test area and the sites must have healed

          -  At least 6 months since prior topical treatment (e.g., 5-fluorouracil or imiquimod)
             for AK

          -  No concurrent therapy that may interfere with clinical evaluations

          -  No concurrent topical drug treatment (e.g., retinoids, aminolevulinic acid, diclofenac
             sodium, imiquimod, or fluorouracil) to any area of skin, including test area

          -  No concurrent enrollment in another clinical trial

          -  No concurrent topical citrus peel or consumption of citrus peel

          -  No chemotherapy for cancer within the past 5 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Stratton, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Cancer Center at University of Arizona Health Sciences Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724-5024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2008</study_first_submitted>
  <study_first_submitted_qc>February 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2008</study_first_posted>
  <results_first_submitted>April 15, 2011</results_first_submitted>
  <results_first_submitted_qc>March 27, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 1, 2015</results_first_posted>
  <last_update_submitted>March 27, 2015</last_update_submitted>
  <last_update_submitted_qc>March 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>actinic keratosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Perillyl alcohol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placbeo</title>
          <description>Patients apply a placebo cream topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.</description>
        </group>
        <group group_id="P2">
          <title>Low Dose POH 0.30%</title>
          <description>Patients apply perillyl alcohol (POH) cream (0.3%) topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.</description>
        </group>
        <group group_id="P3">
          <title>High Dose POH 0.76%</title>
          <description>Patients apply POH cream (0.76%) as in arm II.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I</title>
          <description>Patients apply a placebo cream topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.</description>
        </group>
        <group group_id="B2">
          <title>Arm II</title>
          <description>Patients apply perillyl alcohol (POH) cream (0.3%) topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.</description>
        </group>
        <group group_id="B3">
          <title>Arm III</title>
          <description>Patients apply POH cream (0.76%) as in arm II.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="28"/>
            <count group_id="B4" value="83"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.9" spread="9.9"/>
                    <measurement group_id="B2" value="68.8" spread="10.6"/>
                    <measurement group_id="B3" value="67.6" spread="10.9"/>
                    <measurement group_id="B4" value="67.7" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Histopathology Score of Sun Damaged Skin by Treatment Group</title>
        <description>The histopathologic scoring for skin biopsies from sun-damaged skin to assess the following seven characteristics: 1- atypia (levels 0, 1 &amp; 2), 2- inflammation (grades 0, 1 &amp; 2), 3- hyperkeratosis (loss of basket weave pattern of stratum corneum), 4- parakeratosis (present when there were &gt;3 characteristic nuclei per 40:1 field in stratum corneum), 5- dyskeratosis (focal presence of cells with homogenous, pink cytoplasm n pyknotic nuclei), 6- epidermotropism (lymphocytes migration of &gt;3 cells into epidermis, 7- loss of granular layer. All assessments were done using a 40:1 objective.</description>
        <time_frame>Baseline to 3 months</time_frame>
        <population>change in histopathological scoring was calculated only for participants with baseline and end of study measurements. (n=79)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients apply a placebo cream topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose POH 0.30%</title>
            <description>Patients apply perillyl alcohol (POH) cream (0.3%) topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>High Dose POH 0.76%</title>
            <description>Patients apply POH cream (0.76%) as in arm II.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Histopathology Score of Sun Damaged Skin by Treatment Group</title>
          <description>The histopathologic scoring for skin biopsies from sun-damaged skin to assess the following seven characteristics: 1- atypia (levels 0, 1 &amp; 2), 2- inflammation (grades 0, 1 &amp; 2), 3- hyperkeratosis (loss of basket weave pattern of stratum corneum), 4- parakeratosis (present when there were &gt;3 characteristic nuclei per 40:1 field in stratum corneum), 5- dyskeratosis (focal presence of cells with homogenous, pink cytoplasm n pyknotic nuclei), 6- epidermotropism (lymphocytes migration of &gt;3 cells into epidermis, 7- loss of granular layer. All assessments were done using a 40:1 objective.</description>
          <population>change in histopathological scoring was calculated only for participants with baseline and end of study measurements. (n=79)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.3"/>
                    <measurement group_id="O2" value="-0.1" spread="1.3"/>
                    <measurement group_id="O3" value="0.1" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.10</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.41</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Skin Related Events From Perillyl Alcohol at Administered Doses by Participants</title>
        <description>The events do not have to be caused by the drug or therapy, and they may be mild, moderate, or severe. (NCI)</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients apply a placebo cream topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Low Dose 0.30% POH</title>
            <description>Patients apply perillyl alcohol (POH) cream (0.3%) topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>High Dose 0.76% POH</title>
            <description>Patients apply POH cream (0.76%) as in arm II.</description>
          </group>
        </group_list>
        <measure>
          <title>Skin Related Events From Perillyl Alcohol at Administered Doses by Participants</title>
          <description>The events do not have to be caused by the drug or therapy, and they may be mild, moderate, or severe. (NCI)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No rash, redness, erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No flaking, crusting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No burning or stinging</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No pruritus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild rash, redness, erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild flaking, crusting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild burning or stinging</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild pruritus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate rash, redness, erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate flaking, crusting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate burning or stinging</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate pruritus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months for each participant.</time_frame>
      <desc>Standard Questionnaire</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Patients apply a placebo cream topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.</description>
        </group>
        <group group_id="E2">
          <title>Low Dose POH 0.3%</title>
          <description>Patients apply perillyl alcohol (POH) cream (0.3%) topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.</description>
        </group>
        <group group_id="E3">
          <title>High Dose POH 0.76%</title>
          <description>Patients apply POH cream (0.76%) topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Stent Replacement</sub_title>
                <description>Brief hospitalization for stent replacement</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bowel Obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>SCC in treatment area</sub_title>
                <description>Biopsy sample clinically diagnosed as Actinic Keratoses (AKS), evaluated as squamous cell carcinoma in the histological evaluation.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>SCC outside of treatment area</sub_title>
                <description>One Squamous Cell Carcinoma on left ear (outside of treatment area). One Squamous Cell Carcinoma on cheek.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>BCC outside of treatment area</sub_title>
                <description>Basal Cell Carcinoma on cheek.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Melanoma</sub_title>
                <description>Not in test area</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Mild Rash, Redness, Erythema</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="28"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="27"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Steven P. Stratton, PhD</name_or_title>
      <organization>Arizona Cancer Center</organization>
      <phone>520-626-9295</phone>
      <email>sstratton@azcc.arizona.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

